Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Jul;8(Suppl 3):S254-S256.
doi: 10.21037/tau.2018.12.10.

A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer

Archana Agarwal  1 , Guru Sonpavde  1
Affiliations
Editorial

A new subtyping model for residual invasive disease after cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer

Archana Agarwal et al. Transl Androl Urol. 2019 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: G Sonpavde: Consultant for Bayer, Sanofi, Pfizer, Novartis, Exelixis, Eisai, Janssen, Amgen, Astrazeneca, Merck, Genentech, EMD Serono, Astellas; Research support to institution from Sanofi, Bayer, Boehringer-Ingelheim, Merck, Astrazeneca, BMS, Pfizer; Steering committee of trials sponsored by: Astrazeneca, BMS, Bavarian-Nordic, Astellas; Author for Uptodate; Speaker fees from Clinical Care Options, Physicians Education Resource (PER), Research to Practice (RTP), Onclive. The other author has no conflicts of interest to declare.

Comment on

  • Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.
    Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC. Seiler R, et al. Clin Cancer Res. 2019 Aug 15;25(16):5082-5093. doi: 10.1158/1078-0432.CCR-18-1106. Epub 2018 Sep 17. Clin Cancer Res. 2019. PMID: 30224344

References

    1. Meeks JJ, Bellmunt J, Bochner BH, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2012;62:523-33. 10.1016/j.eururo.2012.05.048 - DOI - PubMed
    1. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-66. 10.1056/NEJMoa022148 - DOI - PubMed
    1. Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29:2171-7. 10.1200/JCO.2010.32.3139 - DOI - PMC - PubMed
    1. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927-34. 10.1016/S0140-6736(03)13580-5 - DOI - PubMed
    1. Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009;115:4104-9. 10.1002/cncr.24466 - DOI - PMC - PubMed